603717 天域生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.064-18.440-52.666-24.726--
总资产报酬率 ROA (%)0.346-3.310-13.779-9.241--
投入资产回报率 ROIC (%)0.533-4.988-20.336-13.355--

边际利润分析
销售毛利率 (%)14.63510.833-34.41811.3267.704
营业利润率 (%)5.640-11.188-84.931-34.186-37.710
息税前利润/营业总收入 (%)11.957-9.631-83.382-31.980-31.620
净利润/营业总收入 (%)7.730-10.835-84.404-28.415-34.566

收益指标分析
经营活动净收益/利润总额(%)-18.49653.41262.3899.50440.938
价值变动净收益/利润总额(%)-3.2500.2456.237-0.582-7.412
营业外收支净额/利润总额(%)28.748-2.8831.583-1.968-2.087

偿债能力分析
流动比率 (X)1.0111.0791.3141.693--
速动比率 (X)0.8490.9131.1861.481--
资产负债率 (%)75.61677.96274.50559.130--
带息债务/全部投入资本 (%)56.83655.96850.30942.066--
股东权益/带息债务 (%)47.53544.09758.272112.619--
股东权益/负债合计 (%)23.06420.69626.48054.637--
利息保障倍数 (X)2.958-7.744-28.604-20.685-5.945

营运能力分析
应收账款周转天数 (天)159.516173.209229.198198.5750.000
存货周转天数 (天)108.17996.56279.76774.2630.000